Literature DB >> 28210940

Syndromic Diagnosis in Evaluation of Women with Symptoms of Vaginitis.

Theophilus Ogochukwu Nwankwo1, Uzochukwu Uzoma Aniebue2, Uchenna Anthony Umeh2.   

Abstract

PURPOSE OF REVIEW: This review aims to determine the effectiveness of the use of syndrome diagnosis in the evaluation of vaginitis and to make suggestions based on the review findings. RECENT
FINDINGS: Vaginal discharge as the main symptom of vaginitis is unspecific. A randomized study of symptom-based diagnosis and treatment of vaginitis in the USA favored symptoms used for treatment; however, this was only a pilot study. Hence, a population-based study is necessary to validate these findings. Most of the study that assessed treatment of vaginitis in pregnancy reported low diagnostic sensitivity and specificity for bacterial vaginosis and vaginal candidiasis and a wide range for trichomonas vaginalis reflecting ineffectiveness of syndrome-based treatment in pregnancy. A systematic review of the web for relevant literature was made, and appropriate articles were extracted and reviewed. Sensitivity, specificity, and positive values were used, where applicable to determine effectiveness. Forty-three full articles and abstracts were reviewed. Studies that validated or applied WHO algorithm for treatment of vaginitis reported high sensitivity (91.5-100%) but moderate to low specificity (0-27.5%) among women with vaginal symptoms. Studies that focused on symptoms for diagnosis of the three main etiologic agents of vaginitis reported low sensitivity and specificity, while such studies in pregnancy reported sensitivity and specificity ranging from 35.4 to 54% for TV, 11 to 100% for BV, and 0 to 56.2% for trichomonas vaginalis, bacterial vaginosis, and vaginal candidiasis, respectively. Studies that added point of care test reported higher sensitivity and specificity and positive predictive value. The use of WHO syndrome-based algorithm or its modification for treatment of vaginitis though moderately effective has the potential for overtreatment and physician error. Point of care testing and laboratory investigation are essential for productive intervention especially in pregnancy.

Entities:  

Keywords:  Bacteria vaginosis; Syndromic evaluation; Trichomonas vaginalis; Vaginal candidiasis; Vaginitis

Year:  2017        PMID: 28210940     DOI: 10.1007/s11908-017-0558-9

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  42 in total

1.  Marginal validity of syndromic management for reproductive tract infections among pregnant women in Jamaica.

Authors:  T Hylton-Kong; A R Brathwaite; G R Del Rosario; S Kristensen; P Kamara; P E Jolly; E W Hook; J P Figueroa; S H Vermund
Journal:  Int J STD AIDS       Date:  2004-06       Impact factor: 1.359

Review 2.  Vaginitis.

Authors:  Barry L Hainer; Maria V Gibson
Journal:  Am Fam Physician       Date:  2011-04-01       Impact factor: 3.292

3.  Risk assessment, symptoms, and signs as predictors of vulvovaginal and cervical infections in an urban US STD clinic: implications for use of STD algorithms.

Authors:  C A Ryan; B N Courtois; S E Hawes; C E Stevens; D A Eschenbach; K K Holmes
Journal:  Sex Transm Infect       Date:  1998-06       Impact factor: 3.519

4.  Office laboratory diagnosis of vaginitis. Clinician-performed tests compared with a rapid nucleic acid hybridization test.

Authors:  D G Ferris; J Hendrich; P M Payne; A Getts; R Rassekh; D Mathis; M S Litaker
Journal:  J Fam Pract       Date:  1995-12       Impact factor: 0.493

Review 5.  Evaluation and management of vaginitis.

Authors:  P L Carr; D Felsenstein; R H Friedman
Journal:  J Gen Intern Med       Date:  1998-05       Impact factor: 5.128

6.  Are a speculum examination and wet mount always necessary for patients with vaginal symptoms? A pilot randomized controlled trial.

Authors:  Matthew Anderson; Andreas Cohrssen; Kathleen Klink; Danit Brahver
Journal:  J Am Board Fam Med       Date:  2009 Nov-Dec       Impact factor: 2.657

7.  Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe laboratory standard.

Authors:  Nancy K Lowe; Jeremy L Neal; Nancy A Ryan-Wenger
Journal:  Obstet Gynecol       Date:  2009-01       Impact factor: 7.661

8.  Prevalence and correlates of cervico-vaginal clinical syndromes among women attending a health camp in Lalitpur district of Nepal.

Authors:  D Johnson; E Chamot; P Lhaki; T R Broker; M Steben; M Steben; S Shrestha
Journal:  Kathmandu Univ Med J (KUMJ)       Date:  2013 Oct-Dec

9.  A Diagnostic and Symptomatological Study on Trichomoniasis in Symptomatic Pregnant Women in Rafsanjan, South Central Iran in 2012-13.

Authors:  Azita Manshoori; Sakineh Mirzaei; Zarrintaj Valadkhani; Mohammad Kazemi Arababadi; Mohsen Rezaeian; Nahid Zainodini; Raza Bahramabadi; Mohammad Zare-Bidaki
Journal:  Iran J Parasitol       Date:  2015 Jul-Sep       Impact factor: 1.012

10.  Trichomonas vaginalis: diagnosis and clinical characteristics in pregnancy.

Authors:  R P Heine; J A McGregor; E Patterson; D Draper; J French; W Jones
Journal:  Infect Dis Obstet Gynecol       Date:  1994
View more
  3 in total

Review 1.  Allergic vulvovaginitis: a systematic literature review.

Authors:  Ana Sofia Oliveira; Joana Rolo; Carlos Gaspar; Rita Palmeira de Oliveira; José Martinez de Oliveira; Ana Palmeira de Oliveira
Journal:  Arch Gynecol Obstet       Date:  2021-11-26       Impact factor: 2.493

2.  Multimodality Screening for Lower Genital Tract Infections Between 18 and 24 Weeks of Pregnancy and its Efficacy in Predicting Spontaneous Preterm Delivery.

Authors:  Vidyashree Ganesh Poojari; Samantha Dawson; Akhila Vasudeva; Nivedita Hegde; Geetha Kaipa; Vandana Eshwara; Chaitanya Tellapragada; Pratap Kumar
Journal:  J Obstet Gynaecol India       Date:  2019-10-15

3.  Associations between sexual habits, menstrual hygiene practices, demographics and the vaginal microbiome as revealed by Bayesian network analysis.

Authors:  Noelle Noyes; Kyu-Chul Cho; Jacques Ravel; Larry J Forney; Zaid Abdo
Journal:  PLoS One       Date:  2018-01-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.